Resminostat is a small molecule histone deacetylase (HDAC) inhibitor that has been investigated for its potential therapeutic use in cancer treatment. It was developed by 4SC AG and is currently in clinical trials for liver cancer and other malignancies. Resminostat's chemical name is N-(4-(hydroxycarbamoyl)phenyl)-4-(pyridin-3-yl)benzamide, and its molecular formula is C19H16N4O3. The product has a formula weight of 348.35 g/mol and a CAS No of 864814-88-0.
Top Ten Keywords and Synonyms:
Health Benefits: Resminostat has potential benefits in cancer treatment, specifically in inhibiting tumor cell growth and promoting apoptosis (cell death). It has been shown to enhance the effectiveness of chemotherapy and radiation therapy in preclinical studies. Clinical trials have demonstrated that resminostat can improve progression-free survival and overall survival rates in patients with advanced hepatocellular carcinoma (HCC).
Potential Effects: The primary effect of resminostat is the inhibition of HDAC activity, which promotes histone acetylation and changes gene expression patterns. This leads to the regulation of key signaling pathways involved in cell proliferation, differentiation, and apoptosis. By targeting these pathways, resminostat can slow down or stop tumor growth and promote cancer cell death.
Product Mechanism: Resminostat is an HDAC inhibitor that targets class I and II HDACs, leading to increased histone acetylation and altered gene expression. This alteration in gene expression can lead to the upregulation of genes involved in apoptosis and the downregulation of genes involved in cell proliferation and angiogenesis. By altering these pathways, resminostat can inhibit tumor growth and induce programmed cell death.
Safety: In clinical trials, resminostat has been generally well-tolerated by patients, with no reported serious adverse events. However, like all drugs, there are potential risks associated with its use. Patients with liver or kidney disease, as well as those taking certain medications, should consult with their healthcare provider before using resminostat.
Side Effects: The most common side effects reported in clinical trials were fatigue, nausea, vomiting, and diarrhea. These side effects were generally mild to moderate in severity and resolved without intervention. Other less common side effects included thrombocytopenia (low platelet count), anemia (low red blood cell count), and neutropenia (low white blood cell count).
Dosing Information: The recommended dose of resminostat varies depending on the type of cancer being treated and the stage of the disease. In clinical trials for liver cancer, the typical dose was 600 mg/day, taken orally. Dosing adjustments may be necessary in patients with renal or hepatic impairment. It is important to follow your healthcare provider's instructions regarding dosing and administration of resminostat.
Conclusion: Resminostat is a promising drug for the treatment of cancer, specifically hepatocellular carcinoma. Its inhibition of HDAC activity leads to altered gene expression and the promotion of programmed cell death. While resminostat has been generally well-tolerated in clinical trials, patients should consult with their healthcare provider before using this medication. With further research, resminostat may prove to be a valuable addition to the treatment options available for cancer patients